资讯
Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
This valuable study presents a novel approach to enhance the therapeutic potential of mesenchymal stromal cells (MSCs) by genetically modifying their glycogen synthesis pathway, resulting in increased ...
Mesenchymal stromal cells (MSCs) are multipotent cell populations obtained from fetal and adult tissues. They share some characteristics with limb bud mesodermal cells such as differentiation ...
Human mesenchymal stromal cells (hMSCs) are widely used in cell therapy because of their ease of harvest, self-renewal, and ability to suppress activation of innate and adaptive immune response.
Background: Mesenchymal stromal cells (MSCs) have emerged as a potential alternative therapeutic strategy for the prophylaxis of graft-versus-host disease (GVHD) in patients undergoing hematopoietic ...
NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...
“Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment option for many disorders of the immune system,” the researchers wrote. “However, clinical trials using MSCs have shown ...
Mesoblast’s Ryoncil ® is the first US FDA-approved mesenchymal stromal cell (MSC) therapy. News release. Mesoblast Limited. December 18, 2024.
Mesenchymal stem cells (MSCs) are derived from stromal tissue and described as multipotent, having the capacity to differentiate into mesodermal and endodermal types of cells, depending on the tissue ...
Newly published results from a Phase I clinical trial suggest that mesenchymal stromal cells (MSCs, a type of cell derived from bone marrow and other bodily tissue) can be used as a safe and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果